A hyaluronic acid-methotrexate conjugate for targeted therapy of rheumatoid arthritis.
In an effort to improve the therapeutic efficacy of methotrexate (MTX), we prepared the hyaluronic acid-MTX conjugate for targeted therapy of rheumatoid arthritis (RA). Owing to the pH-sensitive nature of the conjugate, MTX was rapidly released under the mildly acidic conditions, similar to the environment of inflamed synovial tissue in RA.